… clopidogrel for patients with acute coronary syndrome (ACS) based on randomized clinical
trial data in which ticagrelor reduced major adverse coronary events (MACE) vs clopidogrel …

… for patients with acute coronary syndrome (ACS), primarily based on a single large
randomized clinical trial. The benefits and risks associated with ticagrelor vs clopidogrel in routine …

… benefit than clopidogrel in patients treated with complex interventions or who have remnant
coronary … Recent evidence has suggested a benefit of ticagrelor vs clopidogrel for cardiac …

… Intervention), patients with atrial fibrillation and a recent acute coronary syndrome and
those undergoing percutaneous coronary intervention had less bleeding with apixaban than …

… in Unstable Angina to Prevent Recurrent Events) trial, which first examined extended
treatment with DAPT in ACS (8), a major mechanism underlying the benefit of clopidogrel in …

… the difference in net clinical benefit of clopidogrel plus aspirin compared with ticagrelor plus
… with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) …

… percutaneous coronary intervention (PCI). The past 30 years has seen the progress from early
trials of clopidogrel … to identify a relatively small cohort who would benefit, and (5) the cost …

… acute coronary syndrome (ACS) tend to choose clopidogrel over potent P2Y12 receptor
inhibitor such as ticagrelor after percutaneous coronary intervention (… efficacy of clopidogrel. The …

… an acute coronary syndrome (ACS) or undergo elective percutaneous coronary intervention
… Anticoagulation and Coronary Stenting) comparing clopidogrel with clopidogrel and aspirin …

… of clopidogrel and ticagrelor uses in older patients with an acute coronary syndrome (ACS). …
and ticagrelor had comparable net clinical benefits in patients with ACS aged ≥65 years. …